Octaplas approved for blood-clotting disorders

(HealthDay)—Octaplas has been approved by the U.S. Food and Drug Administration to augment insufficient clotting proteins that could otherwise lead to excessive bleeding or excessive clotting.

The product is a sterile, frozen solution made from . A "solvent detergent process" is applied to minimize the possibility of serious , the agency said.

Octaplas should be matched to the recipient's blood type to help avoid transfusion reactions. Each lot is measured for the required presence of clotting factors before the lot is approved for use, the FDA said.

The current version has been used in Europe and elsewhere since 2006, and a prior formulation was first used in 1992. In all, more than 2 million people have been treated with more than 7 million doses outside the United States, the agency said.

Clinical testing of Octaplas focused on people with liver disease, and heart surgery, the FDA said. The most common adverse reactions were shortness of breath, chest discomfort, skin itchiness and rash, headache and tingling sensations.

Octaplas is produced by Octapharma, based in Vienna, Austria.

More information: The National Library of Medicine has more about bleeding disorders.

add to favorites email to friend print save as pdf

Related Stories

Kyprolis approved for multiple myeloma

Jul 20, 2012

(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.

Varizig approved to reduce chickenpox symptoms

Dec 22, 2012

(HealthDay)—Varizig (varicella zoster immune globulin) has been approved by the U.S. Food and Drug Administration to minimize chickenpox symptoms when administered within four days of exposure to the virus ...

Aubagio approved for multiple sclerosis

Sep 13, 2012

(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

Xarelto's approval expanded

Nov 05, 2012

(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments